Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stock Holdings Lessened by Alliancebernstein L.P.

Alliancebernstein L.P. reduced its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 30.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 93,807 shares of the medical device company's stock after selling 40,640 shares during the period. Alliancebernstein L.P. owned about 0.14% of Tandem Diabetes Care worth $3,379,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. AlphaQuest LLC grew its stake in Tandem Diabetes Care by 138.7% in the fourth quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock worth $34,000 after purchasing an additional 541 shares in the last quarter. Jones Financial Companies Lllp lifted its holdings in Tandem Diabetes Care by 195.8% during the 4th quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock worth $41,000 after buying an additional 748 shares during the last quarter. McIlrath & Eck LLC acquired a new position in shares of Tandem Diabetes Care in the 3rd quarter worth approximately $52,000. Assetmark Inc. increased its holdings in shares of Tandem Diabetes Care by 77.5% in the 4th quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock valued at $44,000 after acquiring an additional 535 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its holdings in shares of Tandem Diabetes Care by 163.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock valued at $65,000 after acquiring an additional 1,101 shares during the last quarter.

Insiders Place Their Bets

In other news, COO Jean-Claude Kyrillos acquired 10,538 shares of the company's stock in a transaction dated Friday, March 7th. The shares were bought at an average price of $18.12 per share, with a total value of $190,948.56. Following the purchase, the chief operating officer now owns 10,538 shares of the company's stock, valued at approximately $190,948.56. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 2.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have weighed in on TNDM shares. Mizuho assumed coverage on shares of Tandem Diabetes Care in a research note on Thursday, April 10th. They set a "neutral" rating and a $20.00 target price for the company. Barclays lowered their price objective on shares of Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. Citigroup cut shares of Tandem Diabetes Care from a "buy" rating to a "neutral" rating and cut their target price for the stock from $35.00 to $24.00 in a report on Tuesday, March 4th. Sanford C. Bernstein lowered Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $35.00 to $25.00 in a report on Friday, February 28th. Finally, Morgan Stanley downgraded Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and cut their price target for the stock from $45.00 to $22.00 in a report on Wednesday, March 5th. Nine equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $43.88.

Tandem Diabetes Care Price Performance

Tandem Diabetes Care stock traded down $0.40 during trading hours on Friday, hitting $16.86. 1,132,393 shares of the company traded hands, compared to its average volume of 1,503,733. Tandem Diabetes Care, Inc. has a 1-year low of $15.75 and a 1-year high of $53.69. The firm has a market cap of $1.12 billion, a P/E ratio of -8.74 and a beta of 1.52. The firm's 50-day simple moving average is $21.77 and its two-hundred day simple moving average is $30.12. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.